



Dynogen Pharmaceuticals, Inc.

52 Second Avenue
Waltham, MA 02451

TEL: 781-839-5100
FAX: 781-839-5200

www.dynogen.com

P R E S S R E L E A S E

For information contact:

Mark Boshar
Dynogen Pharmaceuticals, Inc.
(781) 839-5114
mboshar@dynogen.com

Media:

Kari Watson
MacDougall Biomedical Communications
(508) 647-0209, ext. 11
kwatson@macbiocom.com

FOR IMMEDIATE RELEASE

DYNNOGEN INITIATES PHASE II TRIAL OF DDP733 FOR TREATMENT OF PATIENTS WITH CONSTIPATION-PREDOMINANT IRRITABLE BOWEL SYNDROME

- DDP733 is Dynogen's First Clinical Candidate to Enter Proof-of-Concept Trials -

WALTHAM, Mass., September 28, 2005 – Dynogen Pharmaceuticals, Inc. announced today that it has initiated a Phase II proof-of-concept trial of DDP733 in patients with constipation-predominant irritable bowel syndrome (IBS-c), and the first patients have been dosed. DDP733 is an oral, locally-acting, prokinetic compound that has shown a favorable safety and efficacy profile in preclinical and clinical studies. This DDP733 Phase II trial is a randomized, blinded, placebo controlled study that is enrolling patients with IBS-c at multiple centers in Canada and is assessing safety and pharmacodynamic efficacy as well as symptom-based endpoints.

“The initiation of this Phase II trial is a significant accomplishment for two reasons—it is Dynogen’s first product candidate to enter a human proof-of-concept study and we were able to achieve this important milestone within three years of operation as a company,” said Lee R. Brettman, M.D., FACP, Chief Executive Officer at Dynogen. “We expect to rapidly advance our product pipeline in the coming months with the initiation of a number of additional significant clinical trials.”

“We are very excited about the clinical potential for DDP733, not only because of its prokinetic profile, but also because of our finding that the compound is minimally absorbed. In fact, in our preclinical studies, we found that oral delivery of DDP733 yielded a greater therapeutic benefit than systemic delivery. This is a great advantage for an oral drug in which the desired site of action is the GI tract,” said Dr. Suhail Nurbhai, MRCP, Vice President of Clinical Development at Dynogen. “We believe that the localized action of DDP733 and the fact that it is a partial agonist of the 5-HT₃ receptor will give the

drug favorable safety and efficacy advantages for the treatment of IBS-c. We look forward to confirming this hypothesis in this and future clinical studies.”

About DDP733

DDP733 is an oral, locally-acting, serotonin type 3 receptor (5-HT₃) partial agonist. Serotonin is an important neurotransmitter in the gastrointestinal (GI) system. Previous clinical studies of the compound by Mitsubishi Pharma Corporation and Dynogen demonstrated favorable safety and pharmacokinetic profiles and established the compound’s prokinetic properties (the ability to promote motility of the GI tract). After licensing DDP733 from Mitsubishi in October 2004, Dynogen researchers conducted extensive preclinical studies in animal models of the upper and lower GI tracts to identify the local site of action for the compound in the GI tract and to confirm that the compound’s activity was maximized when delivered orally.

About Irritable Bowel Syndrome (IBS)

Irritable bowel syndrome is a chronic condition that is believed to be caused by the abnormal function (dysfunction) of the muscles and/or nerves of the organs of the GI tract. Patients with IBS experience abdominal pain, discomfort and bloating accompanied by altered bowel habit that can include either diarrhea, constipation or both. IBS has prevalence of up to 12% of the general population and females account for 80% of the patient population with severe cases. It is the most common disease diagnosed by gastroenterologists and one of the most common disorders seen by primary care physicians.

About Dynogen Pharmaceuticals, Inc.

Dynogen is a privately held, neuroscience-based pharmaceutical company developing more effective treatments for genitourinary and gastrointestinal disorders. Today, Dynogen has three clinical development candidates, DDP200 for overactive bladder, DDP225 for diarrhea-predominant irritable bowel syndrome (IBS-d) and chronic functional vomiting (CFV), and DDP733 for constipation-predominant IBS (IBS-c) and nocturnal gastroesophageal reflux disease (n-GERD). More information about the Company can be found by visiting our website www.dynogen.com.

#